Catalyst Pharmaceuticals, Inc. (CPRX) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong revenue and EPS growth with key product expansions, raised guidance, positive analyst sentiment, technical breakout above resistance, and favorable biotech sector tailwinds make it a compelling short-term growth candidate.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High margins ⢠Strong liquidity ⢠Rich valuation CPRX combines high margins, strong cash flow, and an exceptionally liquid balance sheet, but its modest asset efficiency and premium trading multiples limit near-term upside.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Flat Momentum ⢠Tight Range Support Level: $31.15 Resistance Level: $31.14-$31.37 Last month, CPRX held above $31.15 and near the top of its range, but flat momentum and nearby $31.14-$31.37 resistance keep the setup neutral until a breakout.
Sentiment & News
Key News Insights: ⢠Value focus ⢠Momentum strength ⢠Earnings follow-through CPRX continues to screen as an attractive value-and-momentum name, with recent headlines emphasizing valuation upside and a modest post-earnings gain that investors are watching for follow-through.
AI Summary
CPRX is now best viewed as a merger-arbitrage trade around Angelini's all-cash $31.50/share offer, where the main upside is spread capture if the deal closes on time, while the primary risk is legal/process friction from fairness investigations that could delay or complicate completion. #M&Aâ
Description
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company based in Coral Gables, Florida, that develops and sells therapies for rare neuromuscular and neurological disorders in the United States. Its marketed products include amifampridine formulations for adult and pediatric Lambert-Eaton myasthenic syndrome, and the company is advancing that therapy into additional neuromuscular indications such as certain forms of myasthenia gravis and spinal muscular atrophy. Catalyst also maintains licensing and collaboration arrangements with third parties, including BioMarin and Endo Ventures, and was founded in 2002 (renamed to its current corporate identity in 2015).
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | CPRX | Catalyst Pharmaceuticals, Inc. | Strong revenue and EPS growth with key product expansions, raised guidance, positive analyst sentiment, technical breakout above resistance, and favorable biotech sector tailwinds make it a compelling short-term growth candidate. | Closed | +1.9% |